Deke Jiang

southern medical university - china

H指数:29

被引数:2,739

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intestinal dysbiosis exacerbates skin inflammation via microbial metabolite-driven Th2 cell differentiation

肠道菌群失调通过微生物代谢物驱动的Th2细胞分化加剧皮肤炎症

Immunity

IF26.3

2026-04-160

PRE

Omics insights into MYBL2-promoted cancer stem-like cells driving ferroptosis resistance in hepatocellular carcinoma

组学洞察：MYBL2促进的癌症干细胞样细胞驱动肝细胞癌中铁死亡抵抗

Journal of Advanced Research

IF13

2026-03-190

OAAI

A Genome-Wide Association Study on Calcium Nephrolithiasis in Chinese Han Population Identifies Novel Susceptible Loci at 4q35.1, 5q31.2 and 18q21.2

一项关于中国汉族人群钙肾结石的基因组-wide关联研究，鉴定出4q35.1、5q31.2和18q21.2的新易感位点。

Genes

IF2.8

2026-03-100

OAAI

Further insights into the causal link between immune cell phenotypes and autoimmune liver diseases

进一步阐明免疫细胞表型与自身免疫性肝病之间的因果联系

Translational Gastroenterology and Hepatology

IF2.5

2026-01-013

PRE

TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

TCR-based细胞免疫疗法在肝细胞癌中的应用：进展、挑战与展望

cancer immunology immunotherapy

IF0

2025-07-010

Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases

ANNALS OF HEPATOLOGY

IF4.4

2025-01-010

OAAI

A transcriptome-wide association study identified susceptibility genes for hepatocellular carcinoma in East Asia

GASTROENTEROLOGY REPORT

IF4.2

2024-06-051

OAAI

A genetic variant of CXCR4 predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients

JOURNAL OF CLINICAL MICROBIOLOGY

IF5.4

2024-02-142

TRIM16 E121D variant affects the risk and prognosis of hepatocellular carcinoma by modulating the Wnt/β-catenin pathway

MOLECULAR CARCINOGENESIS

IF3.2

2023-07-215

PRE

CXCL13 variant predicts pegylated-interferon a treatment response in HBeAg-positive chronic hepatitis B patients

JOURNAL OF MEDICAL VIROLOGY

IF4.6

2023-07-205

T cell receptor and B cell receptor exhibit unique signatures in tumor and adjacent non-tumor tissues of hepatocellular carcinoma

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-05-294

OAAI

The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2023-03-181

PRE

Differential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy

HEPATOLOGY

IF15.8

2023-03-138

OAAI

A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis

HUMAN MOLECULAR GENETICS

IF3.2

2022-11-294

OAAI

Editorial: tripartite motif 26 inhibits hepatitis B virus replication and its genetic polymorphism predicts response to interferon treatment-towards a better understanding of interferon responsiveness in chronic hepatitis B. Authors' reply

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2022-08-220

PRE

The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma

MOLECULAR CARCINOGENESIS

IF3.2

2022-07-264

PRE

CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients

clinical and translational gastroenterology

IF4.2

2022-06-016

OAAI

An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression

NATURE COMMUNICATIONS

IF15.7

2022-03-0911

OAAI

Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

HEPATOLOGY RESEARCH

IF3.4

2022-02-218

PRE

A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2021-09-018

OAAI

Deke Jiang

个人简介

教育背景

工作经历

荣誉奖项

研究方向